Business Description
Conduit Pharmaceuticals Inc
ISIN : US20678X1063
Description
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | -3.05 | |||||
| Debt-to-Equity | -0.29 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.28 | |||||
| 9-Day RSI | 32.66 | |||||
| 14-Day RSI | 34.9 | |||||
| 6-1 Month Momentum % | -92.83 | |||||
| 12-1 Month Momentum % | -97.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.12 | |||||
| Quick Ratio | 0.12 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 13.81 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -248.73 | |||||
| ROIC % | -458.22 | |||||
| ROC (Joel Greenblatt) % | -2624.77 | |||||
| ROCE % | -995.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.63 | |||||
| EV-to-EBITDA | -0.63 | |||||
| EV-to-FCF | -0.85 | |||||
| Earnings Yield (Greenblatt) % | -158.73 | |||||
| FCF Yield % | -150.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CDT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Conduit Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.22 | ||
| Beta | 0 | ||
| Volatility % | 120.4 | ||
| 14-Day RSI | 34.9 | ||
| 14-Day ATR ($) | 0.013189 | ||
| 20-Day SMA ($) | 0.08498 | ||
| 12-1 Month Momentum % | -97.85 | ||
| 52-Week Range ($) | 0.051 - 5.4399 | ||
| Shares Outstanding (Mil) | 119.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Conduit Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Conduit Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Conduit Pharmaceuticals Inc Frequently Asked Questions
What is Conduit Pharmaceuticals Inc(CDT)'s stock price today?
The current price of CDT is $0.06. The 52 week high of CDT is $5.44 and 52 week low is $0.05.
When is next earnings date of Conduit Pharmaceuticals Inc(CDT)?
The next earnings date of Conduit Pharmaceuticals Inc(CDT) is 2025-02-14 Est..
Does Conduit Pharmaceuticals Inc(CDT) pay dividends? If so, how much?
Conduit Pharmaceuticals Inc(CDT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers